Literature DB >> 11948966

Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate.

Hazem R Ismail A1, France Landry, Armen G Aprikian, Simone Chevalier.   

Abstract

BACKGROUND: Mechanisms triggering prostatic NE differentiation are poorly understood. Since dog and man naturally develop prostatic proliferative diseases with age, our objectives were to confirm the presence of NE cells in the dog prostate and test their hormonal regulation in both species.
METHODS: Serotonin staining was examined by immunohistochemistry in 37 dog prostates: 17 from intact and 20 from castrated animals. In intact dogs, 9 prostates were normal and 8 hyperplastic. In the castrated group, 6 dogs were left untreated while androgens and estrogens were administered to 7 dogs, each. Human prostates were from 48 prostate cancer patients; half of them were submitted to androgen ablation prior to prostatectomy. The density of serotonin-positive NE cells was expressed relatively to the number of acini.
RESULTS: Serotonin-positive NE cells were morphologically similar in dog and human prostates and identified in all groups, independent of the hormonal status. NE cell densities were within the same range in normal and hyperplastic dog prostates but significantly higher after castration. Androgens and estrogens after castration restored NE cell density to normal values and induced luminal differentiation and basal metaplasia, respectively. In human, the density of serotonin-positive NE cells was also significantly higher in benign glands after androgen ablation.
CONCLUSIONS: The dog is a suitable animal model and mimics the human, since androgen ablation favored prostatic NE differentiation in both species. The down-regulation elicited by steroids suggests that the process may be reversible and hormonally-repressed. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948966     DOI: 10.1002/pros.10066

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  22 in total

1.  Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.

Authors:  Xuehong Deng; Han Liu; Jiaoti Huang; Liang Cheng; Evan T Keller; Sarah J Parsons; Chang-Deng Hu
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

2.  Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients.

Authors:  Xuehong Deng; Bennett D Elzey; Jean M Poulson; Wallace B Morrison; Song-Chu Ko; Noah M Hahn; Timothy L Ratliff; Chang-Deng Hu
Journal:  Am J Cancer Res       Date:  2011-08-18       Impact factor: 6.166

Review 3.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

4.  Increased chromogranin A and neuron-specific enolase in rats with chronic nonbacterial prostatitis induced by 17-beta estradiol combined with castration.

Authors:  Song Fan; Zong-Yao Hao; Li Zhang; Xian-Guo Chen; Jun Zhou; Yi-Fei Zang; Sheng Tai; Chao-Zhao Liang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling.

Authors:  Dongxia Ge; Allen C Gao; Qiuyang Zhang; Sen Liu; Yun Xue; Zongbing You
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

6.  Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy.

Authors:  Herbert Augustin; Peter G Hammerer; Markus Graefen; Jüri Palisaar; Fedor Daghofer; Hartwig Huland; Andreas Erbersdobler
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

7.  Myc confers androgen-independent prostate cancer cell growth.

Authors:  David Bernard; Albin Pourtier-Manzanedo; Jesús Gil; David H Beach
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

8.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

Authors:  Juan Miguel Mosquera; Himisha Beltran; Kyung Park; Theresa Y MacDonald; Brian D Robinson; Scott T Tagawa; Sven Perner; Tarek A Bismar; Andreas Erbersdobler; Rajiv Dhir; Joel B Nelson; David M Nanus; Mark A Rubin
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

9.  Utility of FDG-PET in clinical neuroendocrine prostate cancer.

Authors:  Daniel E Spratt; Somali Gavane; Lisa Tarlinton; Shoaib B Fareedy; Michael G Doran; Michael J Zelefsky; Joseph R Osborne
Journal:  Prostate       Date:  2014-06-09       Impact factor: 4.104

10.  Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

Authors:  Audrey Dayon; Leyre Brizuela; Claire Martin; Catherine Mazerolles; Nelly Pirot; Nicolas Doumerc; Leonor Nogueira; Muriel Golzio; Justin Teissié; Guy Serre; Pascal Rischmann; Bernard Malavaud; Olivier Cuvillier
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.